Following breast-conserving surgery for ductal carcinoma in situ (DCIS), younger women face a higher risk than older patients for recurrence of both DCIS and invasive carcinomas.
Oral agents and “watchful waiting” might make it possible to delay or avoid overtreatment with surgery and radiotherapy for many women diagnosed with ductal carcinoma in situ.
Working with Watson, IBM’s Jeopardy!-winning computer, oncologists are developing new supercomputing tools for treatment decision support.
Clear guidelines about the utilization of MRI in breast cancer detection and management are needed, as the modality is being overused in women for whom it offers few benefits (and potential harms), and underused when it might be appropriate.
In this interview we discuss research into cancer vaccines and checkpoint inhibitors for the treatment of breast cancer.
Not all DCIS is dangerous, and the prognostic genomic Oncotype DX DCIS Score allows for routine risk stratification of patients to avoid unnecessary treatment.
In this interview we discuss chemoprevention in breast cancer, including investigational agents and the use of herbal supplements.
Two leading breast cancer experts debated the proposition that platinum-based or other additional systemic agents should be used in difficult-to-treat cases of high-risk triple-negative breast cancer.
In a review of axillary management, it was found that regional node irradiation is likely important in reducing distant metastasis in high-risk breast cancer.
With increasing maternal ages worldwide, patients undergoing breast cancer treatment while pregnant is becoming a more common experience in clinical oncology.